Signal from the log
Airway Therapeutics
50 M$ · Series D and later · United States · Biotech
Biotech d'Atlanta, essaimée en 2011 du Cincinnati Children's Hospital. Elle développe le zelpultide alfa, une protéine D du surfactant obtenue par recombinaison et absente des surfactants commerciaux, pour prévenir la dysplasie broncho-pulmonaire chez les grands prématurés. Sur les 50 M$ annoncés, 26 M$ avaient déjà été levés en SAFE.
Verified
Announced on , logged by the watch of 25 August 2026.
- Operation
- Funding round
- Announced amount
- 50 M$
- Stage
- Series D and later
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Cincinnati Children's
Provenance
Source prnewswire
Logged on 25 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.